ZA201901717B - Polymorphic form of kinase inhibitor compound, pharmaceutical composition containing same, and preparation method therefor and use thereof - Google Patents
Polymorphic form of kinase inhibitor compound, pharmaceutical composition containing same, and preparation method therefor and use thereofInfo
- Publication number
- ZA201901717B ZA201901717B ZA201901717A ZA201901717A ZA201901717B ZA 201901717 B ZA201901717 B ZA 201901717B ZA 201901717 A ZA201901717 A ZA 201901717A ZA 201901717 A ZA201901717 A ZA 201901717A ZA 201901717 B ZA201901717 B ZA 201901717B
- Authority
- ZA
- South Africa
- Prior art keywords
- preparation
- pharmaceutical composition
- composition containing
- kinase inhibitor
- method therefor
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610866253 | 2016-09-29 | ||
| PCT/CN2017/104506 WO2018059556A1 (zh) | 2016-09-29 | 2017-09-29 | 激酶抑制剂化合物的多晶型、含其的药物组合物及其制备方法和应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201901717B true ZA201901717B (en) | 2019-11-27 |
Family
ID=61763329
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA201901717A ZA201901717B (en) | 2016-09-29 | 2019-03-19 | Polymorphic form of kinase inhibitor compound, pharmaceutical composition containing same, and preparation method therefor and use thereof |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US11053224B2 (OSRAM) |
| EP (1) | EP3502105B8 (OSRAM) |
| JP (2) | JP7253491B2 (OSRAM) |
| KR (1) | KR102289684B1 (OSRAM) |
| CN (1) | CN108884080B (OSRAM) |
| AU (1) | AU2017336889B2 (OSRAM) |
| CA (2) | CA3035124C (OSRAM) |
| EA (1) | EA201990688A1 (OSRAM) |
| ES (1) | ES2914294T3 (OSRAM) |
| IL (2) | IL265266B2 (OSRAM) |
| MY (1) | MY194364A (OSRAM) |
| PH (1) | PH12019500681A1 (OSRAM) |
| PL (1) | PL3502105T3 (OSRAM) |
| SG (1) | SG11201901962QA (OSRAM) |
| TW (1) | TWI647224B (OSRAM) |
| WO (1) | WO2018059556A1 (OSRAM) |
| ZA (1) | ZA201901717B (OSRAM) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018059556A1 (zh) * | 2016-09-29 | 2018-04-05 | 贝达药业股份有限公司 | 激酶抑制剂化合物的多晶型、含其的药物组合物及其制备方法和应用 |
| KR102195348B1 (ko) | 2018-11-15 | 2020-12-24 | 에이치케이이노엔 주식회사 | 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물 |
| CA3171563A1 (en) | 2020-03-25 | 2021-09-30 | Charles D. Blizzard | Ocular implant containing a tyrosine kinase inhibitor |
| CN115531352B (zh) | 2020-09-14 | 2025-04-25 | 视点制药公司 | 可生物蚀解的眼部药物递送插入剂及治疗方法 |
| BR112023018649A2 (pt) * | 2021-03-16 | 2023-10-10 | Hk Inno N Corp | Forma cristalina e método para preparar uma forma cristalina |
| JP7138982B1 (ja) | 2021-09-24 | 2022-09-20 | 東海物産株式会社 | アンセリンの結晶及びその製造方法 |
| CA3245205A1 (en) | 2022-03-11 | 2023-09-14 | EyePoint Pharmaceuticals, Inc. | METHOD FOR PREVENTING AGE-RELATED MACULAR DEGENERATION BY ADMINISTRATION OF A DRUG-DELIVERING OPHTHALMIC INSERT |
| TW202345804A (zh) | 2022-03-11 | 2023-12-01 | 美商視點製藥有限公司 | 治療濕性老年黃斑部病變(Wet Age-related Macular Degeneration)之方法 |
| TW202400143A (zh) | 2022-03-11 | 2024-01-01 | 美商視點製藥有限公司 | 用於治療眼睛病況之持續給藥方案 |
| TW202448436A (zh) | 2023-04-11 | 2024-12-16 | 美商視爾普斯眼科公司 | 含有酪胺酸激酶抑制劑之眼部植入物 |
| CN117143083A (zh) * | 2023-08-30 | 2023-12-01 | 沈阳药科大学 | VEGFR抑制剂Vorolanib的合成方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0213185A (pt) | 2001-10-10 | 2004-09-14 | Sugen Inc | Derivados de 3-[4-(heterociclila substituìda)-pirrol-2-ilmetilideno]2-indolinona como inibidores de cinase |
| PL2079727T3 (pl) * | 2006-09-15 | 2016-08-31 | Xcovery Inc | Inhibitory kinazy |
| EP2145505A1 (de) * | 2007-05-07 | 2010-01-20 | Baumer Electric AG | Akustischer wandler |
| US20100256392A1 (en) * | 2007-11-21 | 2010-10-07 | Teva Pharmaceutical Industries Ltd. | Polymorphs of sunitinib base and processes for preparation thereof |
| CA2720943A1 (en) * | 2008-04-16 | 2009-10-22 | Natco Pharma Limited | Novel polymorphic forms of sunitinib base |
| RU2468022C2 (ru) | 2008-05-23 | 2012-11-27 | Шанхай Инститьют Оф Фармасьютикал Индастри | Производные дигидроиндолона |
| EP2186809A1 (en) * | 2008-11-13 | 2010-05-19 | LEK Pharmaceuticals D.D. | New crystal form of sunitinib malate |
| EP2264027A1 (en) | 2009-05-27 | 2010-12-22 | Ratiopharm GmbH | Process for the preparation of N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide |
| CN106928114B (zh) * | 2015-12-31 | 2020-07-28 | 韶远科技（上海)有限公司 | 含有脲基的环状手性氨基类化合物及其可放大工艺和用途 |
| WO2018059556A1 (zh) | 2016-09-29 | 2018-04-05 | 贝达药业股份有限公司 | 激酶抑制剂化合物的多晶型、含其的药物组合物及其制备方法和应用 |
-
2017
- 2017-09-29 WO PCT/CN2017/104506 patent/WO2018059556A1/zh not_active Ceased
- 2017-09-29 TW TW106133830A patent/TWI647224B/zh active
- 2017-09-29 KR KR1020197008752A patent/KR102289684B1/ko active Active
- 2017-09-29 EA EA201990688A patent/EA201990688A1/ru unknown
- 2017-09-29 AU AU2017336889A patent/AU2017336889B2/en active Active
- 2017-09-29 CA CA3035124A patent/CA3035124C/en active Active
- 2017-09-29 JP JP2019538551A patent/JP7253491B2/ja active Active
- 2017-09-29 IL IL265266A patent/IL265266B2/en unknown
- 2017-09-29 PL PL17855006T patent/PL3502105T3/pl unknown
- 2017-09-29 ES ES17855006T patent/ES2914294T3/es active Active
- 2017-09-29 SG SG11201901962QA patent/SG11201901962QA/en unknown
- 2017-09-29 US US16/338,357 patent/US11053224B2/en active Active
- 2017-09-29 CA CA3253105A patent/CA3253105A1/en active Pending
- 2017-09-29 MY MYPI2019000596A patent/MY194364A/en unknown
- 2017-09-29 IL IL311631A patent/IL311631A/en unknown
- 2017-09-29 EP EP17855006.7A patent/EP3502105B8/en active Active
- 2017-09-29 CN CN201780008042.1A patent/CN108884080B/zh active Active
-
2019
- 2019-03-19 ZA ZA201901717A patent/ZA201901717B/en unknown
- 2019-03-28 PH PH12019500681A patent/PH12019500681A1/en unknown
-
2021
- 2021-06-15 US US17/348,482 patent/US12209080B2/en active Active
-
2023
- 2023-03-28 JP JP2023052465A patent/JP7763203B2/ja active Active
-
2025
- 2025-01-27 US US19/038,129 patent/US20250188063A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201901717B (en) | Polymorphic form of kinase inhibitor compound, pharmaceutical composition containing same, and preparation method therefor and use thereof | |
| SG11202104460UA (en) | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors | |
| EP3672973A4 (en) | HETEROCYCLIC COMPOUNDS USED AS KINASE INHIBITORS, COMPOSITIONS INCLUDING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | |
| SG11202011513RA (en) | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | |
| IL254736B (en) | Imidazole [1,2-c]pyrimidine derivative compounds, 1LSD inhibitors, pharmaceutical compound comprising them and use for cancer treatment | |
| ZA201708663B (en) | Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same | |
| IL258082A (en) | Heteroaryl compounds and pharmaceutical preparations containing them | |
| EP3293177A4 (en) | Tyrosine kinase inhibitor and pharmaceutical composition comprising same | |
| EP3412669A4 (en) | TRICYCLIC COMPOUND FOR PROTEIN INHIBITOR CONTAINING BROMODOMAINE AND PREPARATION, PHARMACEUTICAL COMPOSITION AND USE THEREOF | |
| IL323382A (en) | Medicinal products containing Akt protein kinase inhibitors | |
| EP3697791A4 (en) | HETEROCYCLIC COMPOUNDS, COMPOSITIONS INCLUDING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | |
| EP3279207A4 (en) | Novel compound of 4'-thionucleoside, as well as preparation method therefor, pharmaceutical composition thereof and application thereof | |
| IL253538B (en) | Heterocyclic compound and pharmaceutical compound containing it | |
| EP3196194A4 (en) | Preparation method for aromatic heterocyclic compound used as selective jak3 and/or jak1 kinase inhibitor and application of aromatic heterocyclic compound | |
| ZA201805600B (en) | Pyrimidine seven-membered-ring compounds, preparation method therefor, pharmaceutical composition thereof, and uses thereof | |
| IL252901B (en) | Pharmaceutical preparations of tropomyosin-related kinase (trk) inhibitors | |
| SG11202011227VA (en) | Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof | |
| EP3284743A4 (en) | Heterocyclic-imidazole compounds, pharmaceutical compositions thereof, preparation method therefor and use thereof | |
| EP3216791A4 (en) | Polymorphic substance of yonkenafil hydrochloride, preparation method therefor, and composition and use thereof | |
| HUE047537T2 (hu) | Új heterociklusos vegyület, eljárás annak elõállítására, és az azt tartalmazó gyógyászati készítmény | |
| PT3398946T (pt) | Sal de derivado de morfolina e a sua forma cristalina, bem como método de preparação, composição farmacêutica e a sua utilização | |
| EP3650444B8 (en) | Salt and polymorph of benzopyrimidinone compound and pharmaceutical composition and use thereof | |
| IL247645A0 (en) | Preparations of seleno-organic compounds and methods of using them | |
| IL275667A (en) | A compound capable of application as a growth inhibitor, its preparation methods and its use | |
| HK40061096A (en) | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors |